Management of multiple sclerosis

Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists’ Ability to Customize PoNS Therapy® to Improve Gait in People with MS

Retrieved on: 
Monday, February 5, 2024
Therapy, Multiple sclerosis, CSM, HSDT, Gait, Patient, Section, Pons, Physical therapy, DPT, Management of multiple sclerosis, Exposition, APTA, Nursing

CSM attendees can register for the after-hours event at booth 7074 or online at https://forms.gle/FEqwwRZpJj38aJRW9 .

Key Points: 
  • CSM attendees can register for the after-hours event at booth 7074 or online at https://forms.gle/FEqwwRZpJj38aJRW9 .
  • Helius’ appearance at the conference follows the first full year PoNS was available to MS patients in the United States, during which Helius’ engagement with physical therapists grew remarkably.
  • These topics will carry over to the after-hours event, held from 5-6:30 p.m. on February 16 at booth 7074.
  • “PoNS Therapy gives physical therapists a powerful new tool to counter some of the life-changing effects of MS, and we look forward to speaking with physical therapists about PoNS and highlighting its therapeutic potential.”

Helius Medical Technologies, Inc. Receives Letter of Intent from the Québec Ministry of Health and Social Services to Purchase 30 PoNS® Devices

Retrieved on: 
Thursday, October 12, 2023
Management of multiple sclerosis, United, Falling, Gait, Stroke, Letter, Risk, Pons, University, HSDT, Social services, Patient, Pharmaceutical industry, Health

NEWTOWN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it has received a letter of intent (“LOI”) from the Québec Ministry of Health and Social Services (“MSSS”) for the purchase of 30 Portable Neuromodulation Stimulator (“PoNS®”) devices as part of an initiative to assess the value of using PoNS to treat patients suffering symptoms due to stroke.

Key Points: 
  • “Clinical evidence shows that stroke patients treated with PoNS experience significant improvement in gait and balance as well as a reduced risk of falling,” said Dane Andreeff, Helius’ President and Chief Executive Officer.
  • “We are grateful that a second important Canadian healthcare provider has recognized the potential benefits of PoNS Therapy.
  • A few weeks ago, the University of Montreal placed an order for ten PoNS devices to be used in a research study assessing stroke recovery, and the MSSS’s initiative will allow 30 more patients to benefit from PoNS Therapy through MSSS’s funding.
  • We believe this order will accelerate adoption in Canada and, importantly, provide invaluable therapeutic evidence to support Helius’ ongoing efforts to receive authorization for stroke in the United States.”
    The sales of these PoNS devices are expected to commence in the fourth quarter of 2023 and extend through the first quarter of 2024.

Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece

Retrieved on: 
Thursday, September 28, 2023
Management of multiple sclerosis, Helios, CMS, GTIN, Pons, HSDT, UPC, Prescription, Pharmacy, Medicare, PBM, Durable medical equipment, Global Trade Item Number, HCPCS, Wolters Kluwer, GameChanger, Health care

NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that its Portable Neuromodulation Stimulator (“PoNS®”) system and mouthpiece have been assigned universal product code (“UPC”) numbers by Wolters Kluwer Health – Medi-Span® (“Medi-Span”). Medi-Span is the leading automated clinical screening solution– providing a data backbone and vital support to payers, pharmacy benefit managers (“PBMs”), wholesalers, and manufacturers.

Key Points: 
  • The PoNS system has been assigned the Global Trade Item Number (“GTIN”) of 00864288000462, with a direct price of $25,700.
  • Consequently, this will allow Helius to pursue reimbursement through both the pharmacy and the Durable Medical Equipment (“DME”)/HCPCS pathways.
  • “Receiving UPC numbers for the PoNS system and mouthpiece is a gamechanger for Helius,” said Dane Andreeff, Helius’ President and Chief Executive Officer.
  • "We will now be able to reference these UPC numbers as we negotiate reimbursement with third party payers, and prescriptions can be written with these UPC numbers.

Helius to Bring its Innovative PoNS Therapy for Improvement of Gait in People with MS, to the 2023 Academy of Neurologic Physical Therapy Conference

Retrieved on: 
Thursday, September 21, 2023
Management of multiple sclerosis, MedStar National Rehabilitation Hospital, Journal of Neurologic Physical Therapy, Gait, Pons, HSDT, National Physical Laboratory of India, Therapy, Hyatt Regency Savannah, Rehabilitation, Multiple sclerosis, Science, MS, Cerebral cortex, Physical therapy, Knowledge, DPT, Tongue, Conference, Pharmaceutical industry, Nursing

NEWTOWN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it will exhibit at the Academy of Neurologic Physical Therapy 2023 Annual Conference, September 28-30 at the Hyatt Regency Minneapolis, marking its first appearance at the conference.

Key Points: 
  • The Company’s focus at booth 7 will be its innovative Portable Neuromodulation Stimulator (PoNS®), an orally applied therapy delivered by translingual neurostimulation to improve gait deficit in people with multiple sclerosis (“MS”) .
  • Helius’ debut at the conference is timely, coming just after National Rehabilitation Awareness Week (Sept. 18-24) and on the eve of National Physical Therapy Month (October).
  • An individualized physical therapy regimen performed with the PoNS device, mostly in clinic for the first two weeks then at home for twelve additional weeks, is the hallmark of PoNS Therapy™.
  • When used regularly and consistently over the 14-week treatment period, PoNS triggers neuroplastic mechanisms that can lead to significant improvement in gait function .

Helius Medical Technologies to Present at the 2023 Interdisciplinary Association of Functional Neuroscience and Rehabilitation Conference

Retrieved on: 
Wednesday, September 13, 2023
Management of multiple sclerosis, Health, Gait, Pons, HSDT, Stroke, Therapy, Interdisciplinary Association for Population Health Science, Rehabilitation, Multiple sclerosis, Movement, Science, Neuroscience, Patient, Person-centered therapy, Conference, Nursing

NEWTOWN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Antonella Favit-Van Pelt, M.D., Ph.D., Helius’ Chief Medical Officer, will present at the Interdisciplinary Association of Neuroscience and Rehabilitation (IAFNR) Conference from September 28 to October 1, 2023. The IAFNR Conference is a four-day virtual event intended for neuroscience experts, including movement and neuromuscular disorder specialists, physical therapists, and occupational therapists.

Key Points: 
  • -- Presentation to educate on Portable Neuromodulation Stimulator (PoNS®) Therapy, highlighting the differentiation from other neuromodulation technologies, and the science behind its effectiveness, clinical data, safety profile --
    NEWTOWN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Antonella Favit-Van Pelt, M.D., Ph.D., Helius’ Chief Medical Officer, will present at the Interdisciplinary Association of Neuroscience and Rehabilitation ( IAFNR ) Conference from September 28 to October 1, 2023.
  • The IAFNR Conference is a four-day virtual event intended for neuroscience experts, including movement and neuromuscular disorder specialists, physical therapists, and occupational therapists.
  • “The field of neuromodulation-based healthcare is evolving rapidly, and we believe that PoNS Therapy™ is a groundbreaking treatment for people suffering from balance or gait impairment.
  • Our goal has always been to bring this impactful technology to as many qualifying patients as possible, and this forum is an excellent platform to create awareness and engage leading practitioners in neurorehabilitation.”
    Details of the presentation are as follows:

Helius Medical Technologies, Inc. Announces Participation of Montefiore Medical Center in its PoNS® Therapeutic Experience Program

Retrieved on: 
Monday, August 7, 2023
Management of multiple sclerosis, Montefiore Medical Center, Center of excellence, Gait, Pons, HSDT, Patient, Multiple sclerosis, MS, Montefiore, Pharmaceutical industry, Nursing

NEWTOWN, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the addition the Montefiore Medical Center (“Montefiore”) to its PoNS Therapeutic Experience Program (“PoNSTEP”).

Key Points: 
  • NEWTOWN, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the addition the Montefiore Medical Center (“Montefiore”) to its PoNS Therapeutic Experience Program (“PoNSTEP”).
  • Montefiore’s participation in the study will be held at the Burke Rehabilitation Center and led by Dr. Christopher Langston, medical director of The Madlyn Borelli Multiple Sclerosis Center at Montefiore Nyack Hospital.
  • Langston is a renowned clinical researcher of current and advanced topics in MS management and patient-centered care.
  • At Montefiore, we believe it’s important to understand all MS treatments available in order to guide our patients in choosing their best path.

Helius Medical Technologies Announces DMEPOS Accreditation for PoNS

Retrieved on: 
Tuesday, June 20, 2023
Management of multiple sclerosis, Helios, CMS, Legislation, Accreditation, Centers for Medicare & Medicaid Services, Pons, HSDT, The Compliance Team, Stroke, Multiple sclerosis, TCT, Certification, Medicare, Emerging technologies, Andreyev, Health, Organization

The accreditation certifies that Helius has established processes that conform to TCT’s Exemplary Provider® DMEPOS Quality Standards.

Key Points: 
  • The accreditation certifies that Helius has established processes that conform to TCT’s Exemplary Provider® DMEPOS Quality Standards.
  • “We are thrilled that PoNS has been awarded DMEPOS accreditation.
  • “DMEPOS accreditation has particular relevance under the proposed Transitional Coverage for Emerging Technologies (TCET) legislation.
  • TCT’s proprietary accreditation status is known as Exemplary Provider Accreditation® and its industry-leading accreditation model features healthcare’s first comprehensive set of plain language, operations-driven quality standards with expert-led implementation guidance.

DrTalks Announces Multiple Sclerosis and Neuroimmune Summit to Take Place Virtually on July 5 - 11, 2023

Retrieved on: 
Thursday, April 27, 2023
Exercise, Sclerosis, Management of multiple sclerosis, Human, Depression, Diet, PEMF, Wahls, Disability, Anxiety, Life, Quality of life, Constipation, Research, Multimedia, Multiple sclerosis, Newsroom, Autoimmunity, DSM-IV codes, Pulse, MS, MD, Patient, Risk, Functional medicine, Concussion, Paratriathlon, Book, Caregiver, Fatigue, Nursing, Online shopping

CARLSBAD, Calif., April 27, 2023 /PRNewswire/ -- DrTalks is thrilled to unveil its upcoming virtual summit, the Multiple Sclerosis and Neuroimmune Summit , which will be held from July 5th to 11th, 2023.

Key Points: 
  • CARLSBAD, Calif., April 27, 2023 /PRNewswire/ -- DrTalks is thrilled to unveil its upcoming virtual summit, the Multiple Sclerosis and Neuroimmune Summit , which will be held from July 5th to 11th, 2023.
  • The Multiple Sclerosis and Neuroimmune Summit is expected to draw participants from around the world.
  • Registration for the Multiple Sclerosis and Neuroimmune Summit is now open at https://summits.drtalks.com/multiple-sclerosis-summit/ .
  • Don't miss this chance to learn more about multiple sclerosis and get your life back on track.

Helius Medical Technologies to Spotlight Expanded Authorizations for its PoNS Device at 2023 American Academy of Neurology Annual Meeting, Booth 1685

Retrieved on: 
Monday, April 17, 2023
Real, Management of multiple sclerosis, Helios, PMID, Gait, DSM-IV codes, Pons, AAN, HSDT, Stroke, Therapy, Clinical trial, American Academy, Brain, Falls, Multiple sclerosis, MS, Nerve, The United People of Canada, Andreyev, FGA, Rehabilitation, Patient, Annual Meetings of the International Monetary Fund and the World Bank Group, Risk, Traumatic brain injury, DGI, Exhibition, Boston Convention and Exhibition Center, American Academy of Neurology, Health Canada, Tongue, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Dietary supplement, Pharmaceutical industry, Medical device

Helius’s presence at the conference comes at a time when PoNS is seeking additional indications for neurological conditions that lead to gait and/or balance impairment.

Key Points: 
  • Helius’s presence at the conference comes at a time when PoNS is seeking additional indications for neurological conditions that lead to gait and/or balance impairment.
  • Health Canada authorized PoNS for short-term treatment of balance and gait deficit due to MS, mild-to-moderate traumatic brain injury (mmTBI) and, in the past month, stroke .
  • “This is the right time to exhibit at the AAN conference,” said Helius President and Chief Executive Officer Dane Andreeff.
  • Tyler M, Skinner K, Prabhakaran V, Kaczmarek K, Danilov Y. Translingual neurostimulation for the treatment of chronic symptoms due to mild-to-moderate traumatic brain injury.

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 9, 2023
MS, Pons, Clinical trial, HSDT, Introduction, Management of multiple sclerosis, Andreyev, PTAP, Patient, Therapy, Stroke, Health, Center of excellence, Operating cost, Prescription, Video game, Pharmaceutical industry, Cryptocurrency, Helios

NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2022.

Key Points: 
  • Gross profit for the fourth quarter of 2022 was $132 thousand, compared to gross profit of $129 thousand in the fourth quarter of 2021.
  • Operating expenses for the fourth quarter of 2022 decreased to $2.8 million, compared to $4.2 million in the fourth quarter of 2021.
  • Operating loss for the fourth quarter of 2022 decreased $1.4 million to a loss of $2.7 million, compared to an operating loss of $4.1 million in the fourth quarter of 2021.
  • The basic and diluted net loss per share for the fourth quarter 2022 was $0.17, compared to net loss per share of $1.31 in the fourth quarter 2021.